Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates

Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $2.77 per share versus the Zacks Consensus Estimate of a loss of$ 4.21. This compares to loss of $4.80 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 34.20%. A quarter ago, it was expected that this pharmaceutical company would post a loss of$ 3.90 per share when it actually produced a loss of $3.60, delivering a surprise of 7.69%.Over the last four quarters, th ...